What are ABBV's business segments?

AbbVie Inc. (ABBV) reports revenue by product line and geographic region in its 10-K segment disclosures. The composition lists on this page show the most recent breakdown; the expanded table view shows the multi-year transposed history.

Which segment generates the most revenue for ABBV?

AbbVie Inc.'s largest reported segment is SKYRIZI, at $17.56 billion in revenue for fiscal year 2025 (ended December 31, 2025). It sits at the top of the composition list on this page. Segment mix can shift materially year over year, especially after acquisitions, divestitures, or new-product launches — the expand-modal view shows the full trajectory.

How current is ABBV's segment data?

AbbVie Inc. (ABBV)'s segment breakdown on this page is from its most recent annual filing, fiscal year 2025 (ended December 31, 2025). Segment disclosures are reported annually in the 10-K and refresh within 48 hours of each filing.

ABBV

AbbVie Inc.

NYSE·Drug Manufacturers, General · Healthcare

$256.15$2.77+1.09%

After hours·$255.63−0.20%

Market cap$452.56B·Market closed·Jul 21 7:59 PM UTC

Frequently Asked Questions About ABBV

What are ABBV's business segments?: AbbVie Inc. (ABBV) reports revenue by product line and geographic region in its 10-K segment disclosures. The composition lists on this page show the most recent breakdown; the expanded table view shows the multi-year transposed history.
Which segment generates the most revenue for ABBV?: AbbVie Inc.'s largest reported segment is SKYRIZI, at $17.56 billion in revenue for fiscal year 2025 (ended December 31, 2025). It sits at the top of the composition list on this page. Segment mix can shift materially year over year, especially after acquisitions, divestitures, or new-product launches — the expand-modal view shows the full trajectory.
How current is ABBV's segment data?: AbbVie Inc. (ABBV)'s segment breakdown on this page is from its most recent annual filing, fiscal year 2025 (ended December 31, 2025). Segment disclosures are reported annually in the 10-K and refresh within 48 hours of each filing.

ABBV

AbbVie Inc.

NYSE·Drug Manufacturers, General · Healthcare

$256.15$2.77+1.09%

After hours·$255.63−0.20%

Market cap$452.56B·Market closed·Jul 21 7:59 PM UTC

By Product

Latest period2025

Segment	Revenue	Share	YoY Growth %
SKYRIZI	$17.56B	30.2%	+49.9%
RINVOQ	$8.30B	14.3%	+39.1%
H U M I R A	$4.54B	7.8%	−49.5%
Botox Therapeutic	$3.77B	6.5%	+14.8%
Vraylar	$3.62B	6.2%	+10.8%
Imbruvica	$2.87B	4.9%	−14.3%
VENCLEXTA	$2.79B	4.8%	+8.1%
Other Products	$2.63B	4.5%	−13.4%
Other	$12.09B	20.8%	+1.5%

By Geography

Latest period2025

Segment	Revenue	Share	YoY Growth %
UNITED STATES	$46.60B	95.2%	+8.3%
Non-US	$2.36B	4.8%	−82.2%

Frequently Asked Questions About ABBV

What are ABBV's business segments?: AbbVie Inc. (ABBV) reports revenue by product line and geographic region in its 10-K segment disclosures. The composition lists on this page show the most recent breakdown; the expanded table view shows the multi-year transposed history.
Which segment generates the most revenue for ABBV?: AbbVie Inc.'s largest reported segment is SKYRIZI, at $17.56 billion in revenue for fiscal year 2025 (ended December 31, 2025). It sits at the top of the composition list on this page. Segment mix can shift materially year over year, especially after acquisitions, divestitures, or new-product launches — the expand-modal view shows the full trajectory.
How current is ABBV's segment data?: AbbVie Inc. (ABBV)'s segment breakdown on this page is from its most recent annual filing, fiscal year 2025 (ended December 31, 2025). Segment disclosures are reported annually in the 10-K and refresh within 48 hours of each filing.